TY - JOUR
T1 - Nonmyeloablative stem cell transplantation for chronic myeloid leukemia
AU - Qazilbash, Muzaffar H.
AU - Giralt, Sergio A.
AU - Champlin, Richard E.
PY - 2004/6
Y1 - 2004/6
N2 - The current experience with NST in CML shows that it is a feasible treatment option for older patients and patients with comorbidities. GVHD still occurs, but nonrelapse mortality seems to be lower with NST than with conventional myeloablative regimens. Patients with advanced and refractory disease at the time of transplantation do not seem to benefit from this procedure. There is very little published experience with NST after the introduction of imatinib mesylate. The authors currently are conducting a clinical trial that uses imatinib as part of a nonmyeloablative conditioning regimen for CML.
AB - The current experience with NST in CML shows that it is a feasible treatment option for older patients and patients with comorbidities. GVHD still occurs, but nonrelapse mortality seems to be lower with NST than with conventional myeloablative regimens. Patients with advanced and refractory disease at the time of transplantation do not seem to benefit from this procedure. There is very little published experience with NST after the introduction of imatinib mesylate. The authors currently are conducting a clinical trial that uses imatinib as part of a nonmyeloablative conditioning regimen for CML.
UR - http://www.scopus.com/inward/record.url?scp=3242766830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242766830&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2004.03.009
DO - 10.1016/j.hoc.2004.03.009
M3 - Review article
C2 - 15271401
AN - SCOPUS:3242766830
SN - 0889-8588
VL - 18
SP - 703
EP - 713
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 3
ER -